Carmen Bozic Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 week, 1 day ago
Carmen Bozic has an estimated net worth of at least $29.6 million*, as of Dec. 18, 2024. They own 23,259 shares of VRTX stock. They have sold 47,585 shares of VRTX stock since 2021, for an estimated $18.7 million.
Carmen Bozic $VRTX SEC Form 4 Insider Trading
Carmen Bozic has filed a total of 12 insider trades in $VRTX since 2021. Their most recent trade was a sale of 2,280 shares, made on Aug 07, 2024. Their largest trade was a sale of 5,651 shares, made on Oct 31, 2023. We estimate that they now own 23,259 shares of $VRTX, worth an estimated $10.9 million.
Insider Trading at $VRTX
There have been a total of 474 insider trades reported at $VRTX since 2021, with 25,000 shares purchased and 808,928 shares sold. The most active insider traders in $VRTX stock have been David Altshuler, Bastiano Sanna, and Ourania Tatsis. The most recent trade was a sale of 15 shares reported by DAVID ALTSHULER (EVP, Chief Scientific Officer), made on Nov 15, 2024.
History of Insider Stock Trades by Carmen Bozic
Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
---|---|---|---|---|
VRTX | Sale | 2,280 | Aug 07, 2024 | Aug. 8, 2024, 4:06 p.m. |
VRTX | Sale | 2,280 | Jul 24, 2024 | July 25, 2024, 4:06 p.m. |
VRTX | Sale | 2,280 | Jul 10, 2024 | July 12, 2024, 4:07 p.m. |
VRTX | Sale | 2,280 | Jun 26, 2024 | June 28, 2024, 4:04 p.m. |
VRTX | Sale | 2,280 | Jun 12, 2024 | June 13, 2024, 4:11 p.m. |
VRTX | Sale | 2,280 | May 29, 2024 | May 31, 2024, 4:19 p.m. |
VRTX | Sale | 5,650 | Nov 14, 2023 | Nov. 16, 2023, 5:15 p.m. |
VRTX | Sale | 5,651 | Oct 31, 2023 | Nov. 2, 2023, 4:07 p.m. |
VRTX | Sale | 5,651 | Oct 17, 2023 | Oct. 19, 2023, 4:18 p.m. |
VRTX | Sale | 5,651 | Oct 03, 2023 | Oct. 5, 2023, 4:30 p.m. |
VRTX | Sale | 5,651 | Sep 19, 2023 | Sept. 21, 2023, 4:15 p.m. |
VRTX | Sale | 5,651 | Sep 05, 2023 | Sept. 7, 2023, 4:29 p.m. |
$VRTX Executives and Stock Owners with Insider Trades
-
David Altshuler, EVP, Global Research and CSO
-
Bastiano Sanna, EVP, Cell & Genetic Therapies
-
Ourania Tatsis, EVP, Chief Reg. & Quality Off.
-
Stuart A Arbuckle, EVP, COO
-
Charles F Jr Wagner, EVP & Chief Financial Officer
-
Jeffrey M Leiden, Executive Chairman
-
Joy Liu, SVP, General Counsel
-
Reshma Kewalramani, CEO & President
-
Carmen Bozic, EVP and CMO
-
Kristen Ambrose, SVP & Chief Accounting Officer
-
Amit Sachdev, EVP Chief Patient & Ext Af Off
-
Edward Morrow Iii Atkinson, EVP, Chief Technical Ops. Off.
-
Amit Sachdev, EVP, Chief Patient Officer
-
Jonathan Biller, EVP and Chief Legal Officer
-
David Altshuler, EVP, Chief Scientific Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.